Becton, Dickinson and Company (NYSE:BDX) Releases FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY 2026 earnings guidance on Monday. The company provided EPS guidance of 12.350-12.650 for the period, compared to the consensus EPS estimate of 14.810. The company issued revenue guidance of -.

Becton, Dickinson and Company Trading Down 1.3%

BDX stock opened at $207.31 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $235.34. The business has a 50 day simple moving average of $200.14 and a two-hundred day simple moving average of $192.53. The company has a market capitalization of $59.06 billion, a price-to-earnings ratio of 35.56, a PEG ratio of 2.32 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the previous year, the firm earned $3.43 earnings per share. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Becton, Dickinson and Company declared that its Board of Directors has authorized a share buyback plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Jefferies Financial Group boosted their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Barclays initiated coverage on Becton, Dickinson and Company in a research note on Tuesday. They issued an “overweight” rating and a $202.00 price objective on the stock. Morgan Stanley upped their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Stifel Nicolaus boosted their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Five analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $209.82.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 2,463 shares of company stock worth $501,530. Corporate insiders own 0.40% of the company’s stock.

Key Stories Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q1 beat — BDX reported adjusted EPS $2.91 vs. consensus ~$2.81 and revenue $5.25B, with margin improvements despite adjusted EPS being below last year, showing underlying operational strength. Becton Dickinson BDX Q1 2026 Earnings Transcript
• Positive Sentiment: Spin-off/combination closed — BD completed the combination of its Biosciences & Diagnostic Solutions business with Waters, crystallizing the company’s move to a narrower “New BD” focused on medical technology. That structural clarity can make capital allocation and valuation more straightforward. BD Completes Combination with Waters Corporation
• Positive Sentiment: Shareholder cash deployment — Management outlined $4B of cash deployment following the Waters transaction (buybacks/dividend implications), which is supportive for EPS and return of capital. BD Outlines $12.35–$12.65 EPS Guidance and $4B Cash Deployment
• Neutral Sentiment: Analyst / rating context — Some analysts see valuation and leverage as justifying a Hold; revenue restatement news hasn’t materially changed the outlook according to at least one note, leaving sentiment mixed. Analyst Note: Hold Rating, TipRanks
• Negative Sentiment: Lowered FY‑2026 EPS guidance — Management set FY‑2026 adjusted EPS for New BD at $12.35–$12.65, well below prior consensus (~$14.81), explicitly reflecting the sale/spin of the biosciences & diagnostics unit; that reduction in forward earnings is the main driver of downward pressure on the stock. Reuters: Becton Dickinson cuts annual profit forecast
• Negative Sentiment: Market reaction — Shares fell nearly 3% in early trading as the guidance cut and the transition to New BD outweighed the beat and cash plans; coverage notes the beat was overshadowed by the lowered outlook. Investing.com: Shares Fall Nearly 3%

Institutional Trading of Becton, Dickinson and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in shares of Becton, Dickinson and Company by 9,056.3% during the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after buying an additional 5,174,944 shares during the period. State Street Corp raised its holdings in shares of Becton, Dickinson and Company by 3.4% in the third quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier’s stock worth $2,596,496,000 after buying an additional 459,219 shares during the period. UBS Group AG lifted its stake in shares of Becton, Dickinson and Company by 64.7% during the 3rd quarter. UBS Group AG now owns 1,136,673 shares of the medical instruments supplier’s stock worth $212,751,000 after acquiring an additional 446,676 shares during the last quarter. TOMS Capital Investment Management LP purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at $69,934,000. Finally, AQR Capital Management LLC grew its position in Becton, Dickinson and Company by 53.8% in the 3rd quarter. AQR Capital Management LLC now owns 1,033,860 shares of the medical instruments supplier’s stock valued at $190,623,000 after acquiring an additional 361,642 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.